GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, a global biopharma company, covers the month of August 2026. The report was filed on August 18, 2026, and serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the transaction price for American Depositary Shares (ADS) on the New York Stock Exchange (XNYS):
- ADS Price: $49.5200
Material Changes and Transactions
The document details four specific transactions executed on August 14, 2026. All transactions were acquisitions of notional ADS within executive savings or retirement plans following the reinvestment of dividends. There were no sales of shares reported.
| Individual | Position | Plan Type | Volume (ADS) | Price ($) |
|---|---|---|---|---|
| Dr. Hal Barron | Non-Executive Director | Executive Supplemental Savings Plan | 2,279.563 | 49.5200 |
| James Ford | SVP and Group General Counsel | Executive Supplemental Savings Plan | 53.890 | 49.5200 |
| Maya Martinez-Davis | President, US | Executive Supplemental Savings Plan | 82.133 | 49.5200 |
| Dr. Hal Barron | Non-Executive Director | 401(k) Plan | 73.000 | 49.5200 |
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory disclosure of PDMR transactions.
Investor Verification Checklist
- Verify the total aggregate volume of ADS acquired by Dr. Hal Barron across both the Supplemental Savings Plan and 401(k) plan.
- Confirm the market price of GSK ADS on August 14, 2026, to validate the reported transaction price of $49.52.
- Review subsequent filings to determine if these dividend reinvestments align with the company's broader executive compensation strategy.
- Note that this filing contains no operational or financial performance data; refer to the latest Form 20-F or quarterly earnings release for those metrics.